FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1656351664> ?p ?o ?g. }

• W1656351664 endingPage "446" @default.
• W1656351664 startingPage "439" @default.
• W1656351664 abstract "The aim of the present work was to develop a lymph targeted SLN formulation of antiretroviral (ARV) drug and to have an understanding of its underlying mechanism of uptake by the lymphatics. The lymphatics are the inaccessible reservoirs of HIV in human body. Efavirenz (EFV) is a BCS class II, ARV drug that undergoes extensive first pass metabolism. The EFV SLN formulation was prepared using Gelucire 44/14, Compritol 888 ATO, Lipoid S 75 and Poloxamer 188 by hot homogenization technique followed by ultrasonication method, with mean particle size of 168 nm, polydispersity index (PDI) <0.220, and mean zeta potential of -35.55 mV. DSC and XRPD studies revealed change in crystallinity index of drug when incorporated into SLN. In vitro drug release was found to be prolonged and biphasic in PBS pH 6.8. There was no significant change in the mean particle size, PDI, zeta potential and entrapment efficiency of EFV SLN after storage at 30 ± 2°C/60 ± 5%RH for two months. The results from lymphatic transport and tissue distribution study indicate that a significant part of the EFV had by-passed portal system and was recovered in the lymph via chylomicron uptake mechanism. Reduction in the amount (44.70%) of the EFV reaching to liver indicates that major amount of EFV bypasses the liver and thereby, enhances the oral bioavailability of the EFV. A significant amount of EFV was found in spleen, a major lymphatic organ. EFV SLN seems to have potential to target the ARV to lymphatics for the better management of HIV." @default.
• W1656351664 created "2016-06-24" @default.
• W1656351664 creator A5015262426 @default.
• W1656351664 creator A5051761412 @default.
• W1656351664 creator A5053478067 @default.
• W1656351664 creator A5077231166 @default.
• W1656351664 creator A5086903941 @default.
• W1656351664 date "2015-11-01" @default.
• W1656351664 modified "2023-10-17" @default.
• W1656351664 title "Solid lipid nanoparticles (SLN) of Efavirenz as lymph targeting drug delivery system: Elucidation of mechanism of uptake using chylomicron flow blocking approach" @default.
• W1656351664 cites W1976713994 @default.
• W1656351664 cites W1981468523 @default.
• W1656351664 cites W1995567419 @default.
• W1656351664 cites W1995615444 @default.
• W1656351664 cites W2007893172 @default.
• W1656351664 cites W2010016292 @default.
• W1656351664 cites W2021986664 @default.
• W1656351664 cites W2027889438 @default.
• W1656351664 cites W2032678236 @default.
• W1656351664 cites W2034043510 @default.
• W1656351664 cites W2050029045 @default.
• W1656351664 cites W2054189154 @default.
• W1656351664 cites W2071465678 @default.
• W1656351664 cites W2078567611 @default.
• W1656351664 cites W2081926138 @default.
• W1656351664 cites W2083931290 @default.
• W1656351664 cites W2084270646 @default.
• W1656351664 cites W2099636850 @default.
• W1656351664 cites W2100356714 @default.
• W1656351664 cites W2102126716 @default.
• W1656351664 cites W2112929560 @default.
• W1656351664 cites W2114501722 @default.
• W1656351664 cites W2135738686 @default.
• W1656351664 cites W2139802257 @default.
• W1656351664 cites W2171497934 @default.
• W1656351664 cites W261061428 @default.
• W1656351664 cites W309226605 @default.
• W1656351664 doi "https://doi.org/10.1016/j.ijpharm.2015.09.014" @default.
• W1656351664 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26367780" @default.
• W1656351664 hasPublicationYear "2015" @default.
• W1656351664 type Work @default.
• W1656351664 sameAs 1656351664 @default.
• W1656351664 citedByCount "139" @default.
• W1656351664 countsByYear W16563516642016 @default.
• W1656351664 countsByYear W16563516642017 @default.
• W1656351664 countsByYear W16563516642018 @default.
• W1656351664 countsByYear W16563516642019 @default.
• W1656351664 countsByYear W16563516642020 @default.
• W1656351664 countsByYear W16563516642021 @default.
• W1656351664 countsByYear W16563516642022 @default.
• W1656351664 countsByYear W16563516642023 @default.
• W1656351664 crossrefType "journal-article" @default.
• W1656351664 hasAuthorship W1656351664A5015262426 @default.
• W1656351664 hasAuthorship W1656351664A5051761412 @default.
• W1656351664 hasAuthorship W1656351664A5053478067 @default.
• W1656351664 hasAuthorship W1656351664A5077231166 @default.
• W1656351664 hasAuthorship W1656351664A5086903941 @default.
• W1656351664 hasConcept C112705442 @default.
• W1656351664 hasConcept C11772777 @default.
• W1656351664 hasConcept C142462285 @default.
• W1656351664 hasConcept C142724271 @default.
• W1656351664 hasConcept C155672457 @default.
• W1656351664 hasConcept C171250308 @default.
• W1656351664 hasConcept C178790620 @default.
• W1656351664 hasConcept C181152851 @default.
• W1656351664 hasConcept C181389837 @default.
• W1656351664 hasConcept C185592680 @default.
• W1656351664 hasConcept C192562407 @default.
• W1656351664 hasConcept C199529486 @default.
• W1656351664 hasConcept C201253974 @default.
• W1656351664 hasConcept C203014093 @default.
• W1656351664 hasConcept C2778163477 @default.
• W1656351664 hasConcept C2779720271 @default.
• W1656351664 hasConcept C2779820397 @default.
• W1656351664 hasConcept C2780035454 @default.
• W1656351664 hasConcept C2780072125 @default.
• W1656351664 hasConcept C2781432083 @default.
• W1656351664 hasConcept C2993143319 @default.
• W1656351664 hasConcept C3013748606 @default.
• W1656351664 hasConcept C43617362 @default.
• W1656351664 hasConcept C55493867 @default.
• W1656351664 hasConcept C71924100 @default.
• W1656351664 hasConcept C8243546 @default.
• W1656351664 hasConcept C86181022 @default.
• W1656351664 hasConcept C98274493 @default.
• W1656351664 hasConceptScore W1656351664C112705442 @default.
• W1656351664 hasConceptScore W1656351664C11772777 @default.
• W1656351664 hasConceptScore W1656351664C142462285 @default.
• W1656351664 hasConceptScore W1656351664C142724271 @default.
• W1656351664 hasConceptScore W1656351664C155672457 @default.
• W1656351664 hasConceptScore W1656351664C171250308 @default.
• W1656351664 hasConceptScore W1656351664C178790620 @default.
• W1656351664 hasConceptScore W1656351664C181152851 @default.
• W1656351664 hasConceptScore W1656351664C181389837 @default.
• W1656351664 hasConceptScore W1656351664C185592680 @default.
• W1656351664 hasConceptScore W1656351664C192562407 @default.
• W1656351664 hasConceptScore W1656351664C199529486 @default.
• W1656351664 hasConceptScore W1656351664C201253974 @default.

• next